These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31484893)

  • 1. [Methotrexate-associated lymphoproliferative disorders: clinical aspects].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2019; 60(8):932-943. PubMed ID: 31484893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
    Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
    Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
    Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Tokuhira M; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2019; 59(2):72-92. PubMed ID: 31257348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
    Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
    Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
    Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
    Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
    Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.
    Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T
    Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal.
    Inui Y; Matsuoka H; Yakushijin K; Okamura A; Shimada T; Yano S; Takeuchi M; Ito M; Murayama T; Yamamoto K; Itoh T; Aiba K; Minami H
    Leuk Lymphoma; 2015; 56(11):3045-51. PubMed ID: 25721751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.
    Kobayashi Y; Kimura K; Fujitsu Y; Shinkawa K; Muta H; Sonoda KH
    Jpn J Ophthalmol; 2016 May; 60(3):212-8. PubMed ID: 27018050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
    Toyonaga H; Fukushima M; Shimeno N; Inokuma T
    BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-associated lymphoproliferative disorders of the tongue developing in patients with rheumatoid arthritis: a report of 2 cases and a review.
    Hashimoto K; Nagao T; Saito T; Kinoshita H
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e1-5. PubMed ID: 24927637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis].
    Uchida Y; Hokkoku K; Hatanaka Y; Kikuchi Y; Tashiro H; Sonoo M
    Rinsho Shinkeigaku; 2018 Aug; 58(8):485-491. PubMed ID: 30068810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
    Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
    J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
    Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endobronchial Manifestation of Methotrexate-induced Lymphoproliferative Disorder.
    Ikeue T; Kawachi H; Yoshida H; Tanaka E; Noguchi S; Fukao A; Terashita S; Tajiri T; Horikawa S; Sugita T
    Intern Med; 2019 Jun; 58(11):1597-1603. PubMed ID: 30713318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous Regression of Methotrexate-related Lymphoproliferative Disorder with T-cell Large Granular Lymphocytosis.
    Ureshino H; Kadota C; Kurogi K; Miyahara M; Kimura S
    Intern Med; 2015; 54(17):2235-9. PubMed ID: 26328653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.
    Tanaka K; Ichikawa A; Umezawa N; Yamamoto K; Yoshifuji K; Okada K; Nogami A; Umezawa Y; Nagao T; Sakashita C; Mori T; Tohda S; Koike R; Yasuda S; Yamamoto M
    Cancer Sci; 2023 Sep; 114(9):3719-3727. PubMed ID: 37365854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.